Ondansetron

Product manufactured by Proficient Rx Lp

Application Nr Approved Date Route Status External Links
ANDA090469 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage • Prevention Of Nausea And Vomiting Associated With Highly Emetogenic Cancer Chemotherapy, Including Cisplatin ≥50 Mg/m 2 . • Prevention Of Nausea And Vomiting Associated With Initial And Repeat Courses Of Moderately Emetogenic Cancer Chemotherapy. • Prevention Of Nausea And Vomiting Associated With Radiotherapy In Patients Receiving Either Total Body Irradiation, Single High-Dose Fraction To The Abdomen, Or Daily Fractions To The Abdomen. • Prevention Of Postoperative Nausea And/or Vomiting. As With Other Antiemetics, Routine Prophylaxis Is Not Recommended For Patients In Whom There Is Little Expectation That Nausea And/or Vomiting Will Occur Postoperatively. In Patients Where Nausea And/or Vomiting Must Be Avoided Postoperatively, Ondansetron Orally Disintegrating Tablets, Usp Are Recommended Even Where The Incidence Of Postoperative Nausea And/or Vomiting Is Low.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Ondansetron ONDANSETRON ZINC4448

Comments